Fulcrum Therapeutics, Inc. (FULC) Stock Price & Analysis
Fulcrum Therapeutics, Inc. (FULC) rose 2.33% to USD 3.52 as of June 10, 2026 at 00:29 UTC, according to Nexqual real-time market data.
FULC last closed at USD 3.44; the session ranged USD 3.36–3.62 on volume of 3,951,937 shares. Market capitalization is $234.55M, with a 52-week range of USD 2.83–15.74 (NGM). Source: Nexqual, June 10, 2026 at 00:29 UTC.
Key Statistics (as of June 10, 2026 at 00:29 UTC)
| Price | USD 3.52 |
|---|---|
| Change | ▲ 2.33% (up) |
| Previous Close | USD 3.44 |
| Open | USD 3.49 |
| Day Range | USD 3.36 – 3.62 |
| 52-Week Range | USD 2.83 – 15.74 |
| Volume | 3,951,937 shares |
| Market Cap | $234.55M |
| Exchange | NGM |
Technical Analysis (FULC)
Nexqual's technical model rates FULC "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:29 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.59 (oversold) |
| vs SMA50 | Below (USD 6.81) |
| MACD | -0.99 (negative) |
Analyst Ratings (FULC)
Wall Street analysts rate FULC "Hold" based on 8 analysts, with a mean price target of USD 6.63 (range USD 3–18), per Nexqual as of June 10, 2026 at 00:29 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 6.63 |
| High Target | USD 18 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 1 / 5 / 3 |
Earnings (FULC)
| Next Earnings Date | 2026-04-27 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.25 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.31 vs est -0.29 ▼ miss |
| 2025-06-30 | USD -0.28 vs est -0.29 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:29 UTC.
Financials & Fundamentals (FULC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -27.10% |
| Debt / Equity | 1.76 |
| Current Ratio | 34.33 |
| Total Cash | $333.32M |
| Total Debt | $5.87M |
| Free Cash Flow | $-37.74M |
Source: Nexqual, June 10, 2026 at 00:29 UTC.
Financial Health Score (FULC)
Nexqual rates Fulcrum Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:29 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $333M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$64M |
| Efficiency | Critical — ROE -27%, ROA -18.4% |
Ownership (FULC)
| Insider Ownership | +3.86% |
|---|---|
| Institutional Ownership | +108.08% |
| Shares Outstanding | 66.63M |
| Float | 47.97M |
| Short % of Float | +12.14% |
Source: Nexqual, June 10, 2026 at 00:29 UTC.
Leadership (FULC)
Fulcrum Therapeutics, Inc. is led by Alexander C. Sapir (age 58), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:29 UTC.
| CEO, President & Director | Alexander C. Sapir (age 58) |
|---|---|
| Chief Scientific Officer | Jeffrey W. Jacobs (age 62) |
Major Backers & Investors (FULC)
Notable institutional backers of Fulcrum Therapeutics, Inc. include Suvretta Capital Management, LLC, RA Capital Management, L.P., TCG Crossover Management, LLC, according to Nexqual as of June 10, 2026 at 00:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.85% |
| RA Capital Management, L.P. | 9.09% |
| TCG Crossover Management, LLC | 7.88% |
| Braidwell LP | 4.7% |
| Nantahala Capital Management, LLC | 4.58% |
| Siren, L.L.C. | 3.53% |
| First Turn Management, LLC | 3.39% |
| Aberdeen Group plc | 3.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.56% |
| Vanguard Group | 7.97% |
Source: Nexqual, June 10, 2026 at 00:29 UTC.
From Fulcrum Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
- Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
- The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders.
- It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
| BYSI | BeyondSpring, Inc. | USD 1.72 | ▲ 0.58% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 95.48 | ▲ 2.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:29 UTC. This page is informational and not investment advice.